Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Tancini

Showing results (151-160 of 218) with videos related to

Pageof 22
Sort By:
Oncology|January 1, 1992
Effects of a preoperative therapy with interleukin-2 on surgery-induced lymphocytopenia in cancer patientsF Brivio, P Lissoni, E Tisi, et al.
Journal of Biological Regulators and Homeostatic Agents|October 1, 1993
Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatoninP Lissoni, S Barni, A Ardizzoia, et al.
Tumori|June 30, 1988
Alteration of opioid peptide circadian rhythm in cancer patientsS Barni, P Lissoni, F Rovelli, et al.
Journal of Biological Regulators and Homeostatic Agents|March 25, 2005
Biological response modifiers of cancer-related neuroendocrine disorders: efficacy of the long-term dopaminergic agonist cabergoline in the treatment of breast cancer-induced hyperprolactinemiaP Lissoni, M Vaghi, S Pescia, et al.
Oncology Reports|May 21, 2011
Efficacy and tolerability of cancer neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin - a progress report of 200 patients with advanced solid neoplasmsP Lissoni, A Ardizzoia, S Barni, et al.
Archivio Italiano Di Urologia, Andrologia : Organo Ufficiale [Di] Societa Italiana Di Ecografia Urologica E Nefrologica|June 1, 1997
[Immunotherapy for metastatic renal carcinoma with interleukin-2 in a subcutanous administration schedule of short duration. Subcutaneous IL-2 in renal carcinoma]P Lissoni, S Barni, A Ardizzoia, et al.
Tumori|February 28, 1981
Usefulness of chest and skeletal survey to assess the time of relapse in breast cancerJ D Tesoro-Tess, P Valagussa, G Gardani, et al.
The International Journal of Biological Markers|July 1, 1989
Interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors in patients with solid tumors are not correlatedP Lissoni, V Rizzo, S Barni, et al.
Oncology Reports|May 21, 2011
A randomized study of tamoxifen alone versus tamoxifen plus melatonin in estrogen receptor-negative heavily pretreated metastatic breast-cancer patientsP Lissoni, A Ardizzoia, S Barni, et al.
European Journal of Cancer (Oxford, England : 1990)|February 16, 2000
Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical statusP Lissoni, S Barni, M Mandalà, et al.
Pageof 22

Showing results (151-160 of 218) with videos related to

Sort By:
Pageof 22
Oncology|January 1, 1992
Effects of a preoperative therapy with interleukin-2 on surgery-induced lymphocytopenia in cancer patientsF Brivio, P Lissoni, E Tisi, et al.
Journal of Biological Regulators and Homeostatic Agents|October 1, 1993
Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatoninP Lissoni, S Barni, A Ardizzoia, et al.
Tumori|June 30, 1988
Alteration of opioid peptide circadian rhythm in cancer patientsS Barni, P Lissoni, F Rovelli, et al.
Journal of Biological Regulators and Homeostatic Agents|March 25, 2005
Biological response modifiers of cancer-related neuroendocrine disorders: efficacy of the long-term dopaminergic agonist cabergoline in the treatment of breast cancer-induced hyperprolactinemiaP Lissoni, M Vaghi, S Pescia, et al.
Oncology Reports|May 21, 2011
Efficacy and tolerability of cancer neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin - a progress report of 200 patients with advanced solid neoplasmsP Lissoni, A Ardizzoia, S Barni, et al.
Archivio Italiano Di Urologia, Andrologia : Organo Ufficiale [Di] Societa Italiana Di Ecografia Urologica E Nefrologica|June 1, 1997
[Immunotherapy for metastatic renal carcinoma with interleukin-2 in a subcutanous administration schedule of short duration. Subcutaneous IL-2 in renal carcinoma]P Lissoni, S Barni, A Ardizzoia, et al.
Tumori|February 28, 1981
Usefulness of chest and skeletal survey to assess the time of relapse in breast cancerJ D Tesoro-Tess, P Valagussa, G Gardani, et al.
The International Journal of Biological Markers|July 1, 1989
Interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors in patients with solid tumors are not correlatedP Lissoni, V Rizzo, S Barni, et al.
Oncology Reports|May 21, 2011
A randomized study of tamoxifen alone versus tamoxifen plus melatonin in estrogen receptor-negative heavily pretreated metastatic breast-cancer patientsP Lissoni, A Ardizzoia, S Barni, et al.
European Journal of Cancer (Oxford, England : 1990)|February 16, 2000
Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical statusP Lissoni, S Barni, M Mandalà, et al.
Pageof 22